BDX

Becton Dickinson and Co
D

BDX

Arincen48/100B

If you had invested in Becton Dickinson and Co ago, it would be worth $1,958 today, against $4,081 in SPY and $6,291 in QQQ.

ArincenArincen ScoreBeta

48/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation5

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2026; the price as of today.

Becton Dickinson and Co key facts

Style
Blend stock · 3.9/10Growth 2.3 · Value 3.4 · Dividend 3.9
Day range
216.580 – 219.750
52-week range
138.310 – 219.750
Market capitalization
59.40B USD
P/E
53.06
PEG ratio
0.61
EPS
4.11
Div Yield
1.94%
EPS growth forecast (FY2027)
+5.4%
Volume
98,213
Beta
0.28
ESG score
72.8/100Environment 85 · Social 69 · Governance 65
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Thomas E. Polen Jr.
Employees
60K
Website
bd.com
IPO date
21 Feb 1973

Becton Dickinson and Co earnings

Next earnings · Q1 FY2027
EPS estimate
2.35 USD
Revenue estimate
4.50B USD
Last quarter · Q4 FY2026
EPS4.15Beat +2.0%Revenue5.27BBeat +3.1%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q4 FY20274.35——+4.78%5.38B——+1.97%
Q3 FY20273.50——+8.40%5.07B——+1.77%
Q2 FY20273.03——+4.32%4.79B——+1.68%
Q1 FY20272.35——+2.62%4.50B——+0.40%
Q4 FY20264.074.15+1.97%+4.80%5.11B5.27B+3.14%-10.46%
Q3 FY20263.143.23+2.87%-12.23%4.89B4.98B+1.96%-9.55%
Q2 FY20262.782.90+4.32%-13.43%4.67B4.71B+0.90%-10.58%
Q1 FY20262.212.29+3.62%-33.24%5.15B4.49B-12.84%-13.20%
Q4 FY20253.923.96+1.02%+3.94%5.91B5.89B-0.27%+8.33%
Q3 FY20253.403.68+8.24%+5.14%5.49B5.51B+0.41%+8.94%

Analysts' estimates for FY2027 over the last 7 days:EPS Revenue How the estimates moved

Becton Dickinson and Co analyst forecast

12-month price target
200.57 USD
-8.02%

Analysts' 1-year price targets range from 165.00 to 242.00, with an average of 200.57.

Past year
1-year forecast
Strong sellStrong buy
Buy
13 ratings
Buy
7
Hold
5
Sell
1

12-month price target

Highest target242.00
Average target200.57
Lowest target165.00
Current price218.07

Becton Dickinson and Co valuation

Price to earnings ratio (TTM)
53.06
Forward P/E (FY2027)
16.45
Price to sales (TTM)
2.94
Price to book
1.17
EV / EBITDA (TTM)
15.41

Capital structure

Market capitalization
59.40B USD
+
Total debt
14.37B USD
−
Cash and short-term investments
733.00M USD
=
Enterprise value
73.03B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)15.33————
FY2027 (est.)16.4515.33———
Now (TTM)53.0616.302.941.1715.41
FY202643.5513.512.560.9813.78
FY202525.2011.611.931.6612.21
FY202432.2316.782.722.1215.49
FY202340.9034.043.002.2616.72
FY202229.5418.242.651.9714.90

Becton Dickinson and Co against its own history

Each figure in the latest fiscal year against the same figure from FY2022 to FY2026: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Medline, ResMed, West Pharmaceutical Services, Intuitive Surgical, Solventum, and Baxter International, the US Medical - Instruments & Supplies companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median52.5
    23.563.0
  • Gross marginHighest in 5 years47.4%
    42.2%47.4%
    Against its peers: 4 of 7Peers' median 44.7%
  • Operating marginBelow its median11.6%
    10.9%12.1%
    Against its peers: 5 of 7Peers' median 23.1%
  • Net marginLowest in 5 years5.9%
    5.9%9.4%
    Against its peers: 5 of 7Peers' median 17.4%
  • Return on equityLowest in 5 years2.3%
    2.3%7.0%
    Against its peers: 6 of 7Peers' median 15.8%
  • Free cash flow marginAbove its median15.1%
    8.8%15.2%
    Against its peers: 4 of 7Peers' median 9.9%
  • Revenue growthLowest in 5 years-10.9%
    -10.9%8.2%
    Against its peers: 7 of 7Peers' median 8.1%
  • EPS growthLowest in 5 years-29.8%
    -29.8%18.6%
    Against its peers: 6 of 6Peers' median 9.4%
  • Debt to EBITDALowest in 5 years3.12×
    3.12×4.48×
    Against its peers: 5 of 7Peers' median 1.26×
  • Current ratioHighest in 5 years8.81
    1.048.81
    Against its peers: 1 of 7Peers' median 3.06

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Becton Dickinson and Co growth and profitability

Revenue (TTM)
20.22B USD
Net income (TTM)
1.14B USD
Gross margin
47.01%
Operating margin
11.58%
Net margin
5.66%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202619.46B-10.91%1.15B-31.70%47.36%11.59%5.89%4.61B-7.06%
FY202521.84B+8.23%1.68B-1.58%45.44%11.80%7.68%4.96B+2.86%
FY202420.18B+4.16%1.71B+14.89%45.22%11.88%8.45%4.82B+9.47%
FY202319.37B+2.66%1.48B-16.58%42.17%10.90%7.66%4.40B-0.18%
FY202218.87B-1.36%1.78B-14.96%44.92%12.09%9.43%4.41B+0.43%

Becton Dickinson and Co revenue breakdown

By product

FY2025
Medical: 52.5%Interventional: 23.9%Life Sciences: 23.7%52.5%Medical23.9%Interventional23.7%Life Sciences
SegmentRevenueShare of revenueChange on the year
Medical11.46B52.5%+13.7%
Interventional5.22B23.9%+4.8%
Life Sciences5.17B23.7%-0.5%

By region

FY2025
United States: 58.6%Europe: 21.7%Asia: 14.2%Others Country: 5.6%58.6%United States21.7%Europe14.2%Asia5.6%Others Country
RegionRevenueShare of revenueChange on the year
United States12.79B58.6%+9.7%
Europe4.73B21.7%+7.4%
Asia3.09B14.2%+6.4%
Others Country1.23B5.6%+1.7%

How Becton Dickinson and Co makes its money

Revenue19.46B 100.0%
Cost of revenue10.24B 52.6%
Gross profit9.21B 47.4%
Research and development988.00M 5.1%
Selling and administration4.97B 25.5%
Other operating expenses1.01B 5.2%
Operating income2.26B 11.6%
Tax388.00M 2.0%
Other expense722.00M 3.7%
Net income1.15B 5.9%

FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Becton Dickinson and Co dividends

Annual dividend
4.24 USD
Dividend yield (indicated)
1.94%
Payout ratio
122.52%
Years of dividend growth
36
Frequency
Quarterly
Next payment
1.06 USD
Next ex-dividend date
10 Dec 2026
Next payment date
31 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share3.283.062.892.752.572.452.382.312.252.08

Becton Dickinson and Co financial health

Cash and short-term investments
733.00M USD
Total debt
14.37B USD
Net cash
-13.63B USD
Free cash flow (TTM)
2.81B USD
Current ratio
8.81
Debt to equity
0.28
Piotroski score
8 / 9
Altman Z-score
2.07

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY2026733.00M14.37B2.93B
FY2025859.00M19.18B2.67B
FY20242.30B21.59B3.07B
FY20231.42B16.82B2.12B
FY20221.17B16.57B1.66B

Becton Dickinson and Co ownership

Institutions
95.48%
Institutional holders
1,473 (-36)
Free float
99.80%

Who owns the shares

Institutions 95.5% Others 4.5%
As of 30 Jun 2026

Shares free to trade

Free float 271.83M shares ·99.8% Closely held 556.76K shares ·0.2%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 2026010.0076.00
Q3 20260557.90K92.48K
Q2 20260636.50K43.99K
Q1 20260624.89K8.42K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2026278.49M279.94M-2.50%
FY2025286.61M287.12M-1.34%
FY2024289.76M291.01M+0.91%
FY2023286.28M288.39M+0.36%
FY2022285.01M287.36M-1.62%

Source: Financial Modeling Prep

Related Instruments

Title: Becton Dickinson and Co

Sector: Healthcare
Industry: Medical - Instruments & Supplies
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Common questions about Becton Dickinson and Co stock